|
|
Carisma Therapeutics Inc (NASDAQ: CARM) |
|
Price: $0.2179
$0.01 
2.832%
|
| Day's High:
| $0.2296
| Week Perf:
| 2.16 %
|
| Day's Low: |
$ 0.21 |
30 Day Perf: |
-47.59 % |
| Volume (M): |
88 |
52 Wk High: |
$ 1.90 |
| Volume (M$): |
$ 19 |
52 Wk Avg: |
$0.86 |
| Open: |
$0.21 |
52 Wk Low: |
$0.16 |
|
|
| Market Capitalization (Millions $) |
9 |
| Shares
Outstanding (Millions) |
41 |
| Employees |
46 |
| Revenues (TTM) (Millions $) |
20 |
| Net Income (TTM) (Millions $) |
-60 |
| Cash Flow (TTM) (Millions $) |
-60 |
| Capital Exp. (TTM) (Millions $) |
0 |
Carisma Therapeutics Inc
Carisma Therapeutics Inc is a biotechnology company that specializes in developing innovative cellular immunotherapies for the treatment of cancer. Their main focus is on developing chimeric antigen receptor (CAR) T-cell therapies, which involve genetically engineering a patient's own immune cells to target and destroy cancer cells. Carisma Therapeutics aims to leverage their expertise in gene editing and cell manufacturing to develop safe and effective therapies that can address the limitations of traditional cancer treatments. The company is committed to advancing the field of immunotherapy and improving patient outcomes by harnessing the power of the immune system to fight cancer.
Company Address: 3675 Market Street Philadelphia 19104 PA
Company Phone Number: 491-6422 Stock Exchange / Ticker: NASDAQ CARM
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Stocks on the Move
Published Wed, Jul 10 2024 5:05 AM UTC
Carisma Therapeutics Appoints New Board Members, Strengthens LeadershipCarisma Therapeutics Inc. (Nasdaq: CARM) recently announced the appointment of Marella Thorell and Dr. David Scadden to its Board of Directors, effectively strengthening the company s leadership team. Their appointments come as the biopharmaceutical company aims to enhance its capabilities in the developm...
|
| Stocks on the Move
Published Wed, Jul 3 2024 12:54 PM UTC
Carisma Therapeutics Inc, a clinical-stage biopharmaceutical company focused on innovative immunotherapies, has experienced a period of trailing performance compared to the rest of the market. This article aims to examine recent articles and events related to Carisma Therapeutics to garner insights into the reasons behind this performance trend. Analysis:1. Carisma Therapeut...
|
| Carisma Therapeutics Inc
Investors are closely monitoring the latest financial results from Carisma Therapeutics Inc. (Nasdaq: CARM) as the company released its first quarter of 2024 financial report. The report showed a significant improvement in the company's performance compared to a year ago, with a reduced shortfall per share and a notable increase in revenue.
According to the report, Carisma realized a shortfall per share of $-0.46 for the first quarter of 2024, compared to $-1.93 in the same quarter the previous year. Additionally, revenue advanced by 4.749% to $3.40 million from the comparable quarter a year ago. However, the company still experienced a net shortfall of $-37.956 million for the quarter, larger than the $-24.642 million reported a year ago.
|
| Carisma Therapeutics Inc
Carisma Therapeutics Inc Faces Challenges as Stock Drops and Revenue Declines in Q2
PHILADELPHIA, March 21, 2024 - Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical-stage biopharmaceutical company specializing in immunotherapies, has recently experienced a decline in its financial performance, leading to a drop in stock prices. The company's stock plummeted by -23.64% over the past 30 days, bringing its share price down by -5.74% during the second quarter of 2024. As a result, the stock has reached its 52-week low.
Carisma's financial span closing on December 31, 2023, revealed some concerning figures. Despite a positive development of reaching a break-even point of $0.00 per share in comparison to the previous year's $-0.02 per share, the company experienced a sharp decline in revenue. Revenue fell by -89.278% to $4.29 million, a significant drop from $40.00 million in the same quarter a year before. Sequentially, revenue did increase by 12.072% from $3.83 million, but the overall trend remains negative.
|
| Carisma Therapeutics Inc
Carisma Therapeutics Inc, a prominent biotechnology company, recently disclosed its financial results for the time-frame ending September 30, 2023. The company recorded $3.827 million in revenue, reflecting a decrease from the previous year. Additionally, Carisma reported a significant net deficit of $-42.806 million, in contrast to prior earnings of $20.457 million. These financial results raise concerns about the company's overall performance and future prospects. Moreover, the recent decline in Carisma Therapeutics Inc stock suggests a challenging market environment for the company. This article aims to analyze these financial facts and provide insights into the potential contextual implications for Carisma Therapeutics Inc.
1. Revenue Decline:
Carisma Therapeutics Inc's revenue of $3.827 million for the financial time-frame ending September 30, 2023, indicates a decline in performance compared to the previous year. This decrease may be attributed to various factors such as increased competition, delays in product development, or changes in market demand. The company needs to address these challenges to regain momentum and achieve sustainable revenue growth.
|
| Per Share |
Current |
| Earnings (TTM) |
-1.45 $ |
| Revenues (TTM) |
0.47 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.43 $
|
| Book Value |
-
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.45 $
|
| Revenues (TTM) |
0.47 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.43 $
|
| Book Value |
- |
| Dividend (TTM) |
0 $ |
|
|
|
|
